ZYDUSLIFE - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:04 am

IntraDay Trade Rating: 3.9

📊 Analysis: ZYDUSLIFE is trading at 920 ₹, below DMA 50 (947 ₹) and DMA 200 (961 ₹), indicating short-term weakness. RSI at 40.8 suggests neutral-to-weak momentum, while MACD negative (-9.67) confirms bearish bias. However, volume (8,28,140) is significantly higher than weekly average (5,83,593), showing strong participation. Fundamentals remain robust with high ROCE (30.6%) and ROE (31.2%), supported by strong quarterly PAT growth (385 Cr. to 1,157 Cr.). Overall, ZYDUSLIFE is a fair candidate for intraday trading with cautious bullish bias if momentum improves.

💰 Optimal Buy Price: 918–922 ₹ (near current support zone).

📈 Profit-Taking Levels: 935–940 ₹ (first resistance), 950–955 ₹ (second resistance near DMA 50).

⚠️ Stop-Loss: 910 ₹ (below recent support).

⏱️ If Already Holding: Exit intraday if price fails to sustain above 925 ₹ or if RSI dips below 40 with MACD remaining negative. Weakness below 918 ₹ should trigger exit to protect capital.

Positive

• ✅ Strong ROCE (30.6%) and ROE (31.2%) indicate excellent capital efficiency.
• ✅ EPS of 48.0 ₹ reflects solid profitability.
• ✅ PEG ratio of 0.26 suggests attractive growth valuation.
• ✅ Dividend yield of 1.20% supports investor sentiment.
• ✅ Quarterly PAT surged from 385 Cr. to 1,157 Cr., showing strong operational performance.

Limitation

• ⚠️ Current price below DMA 50 and DMA 200 confirms weak trend.
• ⚠️ RSI at 40.8 and negative MACD (-9.67) show weak momentum.
• ⚠️ DII holdings declined (-0.23%), showing reduced domestic institutional support.
• ⚠️ Debt-to-equity ratio of 0.35 adds moderate leverage risk.

Company Negative News

• 📉 Decline in DII holding (-0.23%) shows reduced domestic institutional confidence.

Company Positive News

• 📈 FII holdings increased (+0.21%), reflecting foreign investor support.
• 📈 Quarterly PAT growth (+46.4%) highlights strong earnings momentum.

Industry

• 🏭 Industry P/E at 30.6 is higher than company’s P/E (19.2), showing ZYDUSLIFE trades at discount.
• 🏭 Pharma sector remains demand-driven, supported by global healthcare needs and domestic expansion.

Conclusion

📌 ZYDUSLIFE is a fair candidate for intraday trading with cautious bullish bias. Buy near 918–922 ₹ with profit targets at 935–940 ₹ and 950–955 ₹. Maintain strict stop-loss at 910 ₹. If already holding, exit on failure to sustain above 925 ₹ or if RSI/MACD momentum weakens.

Would you like me to extend this into a peer benchmarking overlay so you can compare ZYDUSLIFE against other pharma peers for intraday confirmation, or keep the focus on single-stock execution logic?